Evidence map›Paper›PMID 34965168›Full record

ReviewCirculation2022

Colchicine in Cardiovascular Disease: In-Depth Review.

Spyridon G Deftereos, Frans J Beerkens, Binita Shah, George Giannopoulos, Dimitrios A Vrachatis, Sotiria G Giotaki, Gerasimos Siasos, Johny Nicolas, Clare Arnott, Sanjay Patel and 4 more

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07762807 (Colchicine And Dialysis Patients; a Feasibility Study), which is not on this map. Cited by 166 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 8 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07762807 narecruitingnot on this mapstarted 2025, after this paper: background citation

Colchicine And Dialysis Patients; a Feasibility Study

TypeinterventionalSponsorKing's College LondonRan2025 to 2027Enrolled100ConditionsHaemodialysis Patients, Colchicine, Feasibility StudyArmsColchicine 0.5 mg
3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 8 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025
    Pooled it
  6. Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Inflammation and day-to-day occurrence of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  10. Trial
  11. Review
  12. Article
  13. Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Mitigation of micropollutant toxicity in treated wastewater using the HEnvironmental science and pollution research international · 2026
    Article
  18. Article
  19. Review
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 5 countries.

Spyridon G DeftereosMedical School, National Kapodistrian University of Athens, Greece (S.G.D., D.A.V., S.G.G., G.S., G.D.D.).
Frans J BeerkensMount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (F.J.B., J.N., J.C.K., G.D.D.).
Binita ShahVA New York Harbor Healthcare System, New York University School of Medicine, New York (B.S.).ORCID 0000-0001-8872-8001
George GiannopoulosMedical School, Aristotelian University, Thessaloniki, Greece (G.G.).
Dimitrios A VrachatisMedical School, National Kapodistrian University of Athens, Greece (S.G.D., D.A.V., S.G.G., G.S., G.D.D.).ORCID 0000-0002-2385-5365
Sotiria G GiotakiMedical School, National Kapodistrian University of Athens, Greece (S.G.D., D.A.V., S.G.G., G.S., G.D.D.).
Gerasimos SiasosMedical School, National Kapodistrian University of Athens, Greece (S.G.D., D.A.V., S.G.G., G.S., G.D.D.).ORCID 0000-0001-7601-8870
Johny NicolasMount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (F.J.B., J.N., J.C.K., G.D.D.).ORCID 0000-0002-3015-3361
Clare ArnottThe George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (C.A.).
Sanjay PatelDepartment of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, University of Sydney, Australia (C.A., S.P.).
Mark ParsonsDepartment of Neurology, Liverpool Hospital and Ingham Institute for Applied Medical Research at South Western Sydney Clinical School, University of New South Wales, Australia (M.P.).ORCID 0000-0001-8874-2487
Jean-Claude TardifMontreal Heart Institute, Université de Montréal, Canada (J.-C.T.).ORCID 0000-0002-8200-8983
Jason C KovacicMount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York (F.J.B., J.N., J.C.K., G.D.D.).ORCID 0000-0003-4555-769X
George D DangasMedical School, National Kapodistrian University of Athens, Greece (S.G.D., D.A.V., S.G.G., G.S., G.D.D.).ORCID 0000-0001-7502-8949
National and Kapodistrian University of Athens · GRMount Sinai Hospital · USRoyal Prince Alfred Hospital · AUIngham Institute · AUMontreal Heart Institute · CATelio (Norway) · NOVA NY Harbor Healthcare System · USVictor Chang Cardiac Research Institute · AU

Funding

Therapeutic Mechanisms of Cardiac Progenitors in Ischemic CardiomyopathyR01HL135093 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FISH, KENNETH MICHAEL, KOVACIC, JASON CIRIL · 2017 to 2020
$3.4M
Understanding the Molecular Mechanisms of Fibromuscular DysplasiaR01HL148167 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KADIAN-DODOV, DANIELLA, KOVACIC, JASON CIRIL · 2020 to 2023
$2.8M
Studies on the effects of colchicine on neutrophil biology in acute myocardial infarctionR01HL146206 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SHAH, BINITA · 2019 to 2022
$2.4M
Toward Therapeutic Manipulation of Endothelial to Mesenchymal TransitionR01HL130423 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ISHIKAWA, KIYOTAKE, KOVACIC, JASON CIRIL · 2016 to 2020
$2.1M
Anti-inflammatory therapy during percutaneous coronary interventionIK2CX001074 · VA · VA MEDICAL CENTER · PI SHAH, BINITA · 2016 to 2021
–
CSRD VA IK2 CX001074NHLBI NIH HHS R01 HL130423NHLBI NIH HHS R01 HL135093NHLBI NIH HHS R01 HL146206NHLBI NIH HHS R01 HL148167
6 · The paper itself

Abstract

Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects, however, that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in postoperative and postablation atrial fibrillation, postpericardiotomy syndrome, coronary artery disease, percutaneous coronary interventions, and cerebrovascular disease. We aim to summarize colchicine's pharmacodynamics and the mechanism behind its anti-inflammatory effect, outline thus far accumulated evidence on treatment with colchicine in cardiovascular disease, and present ongoing randomized clinical trials. We also emphasize real-world clinical implications that should be considered on the basis of the merits and limitations of completed trials. Altogether, colchicine's simplicity, low cost, and effectiveness may provide an important addition to other standard cardiovascular therapies. Ongoing studies will address complementary questions pertaining to the use of low-dose colchicine for the treatment of cardiovascular disease.

Indexed as

Cardiovascular DiseasesColchicineGout SuppressantsHumansColchicineGout Suppressantsatrial fibrillationcerebrovascularcolchicinecoronary artery diseasedisordersinflammationpercutaneous coronary interventionpericarditispostpericardiotomy syndrome

Identifiers

PMID34965168
PMCPMC8726640
OpenAlexW4206132566

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.